Autolus Therapeutics Ltd – (AUTL) Receives $44.00 Average Price Target from Analysts

Autolus Therapeutics Ltd – (NASDAQ:AUTL) has received a consensus rating of “Buy” from the six ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $44.00.

A number of research firms have recently commented on AUTL. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of Autolus Therapeutics in a research note on Friday, November 2nd. Wells Fargo & Co restated a “buy” rating and set a $50.00 price objective (up from $38.00) on shares of Autolus Therapeutics in a research note on Thursday. Finally, Zacks Investment Research downgraded shares of Autolus Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday.

Shares of NASDAQ AUTL opened at $39.02 on Friday. Autolus Therapeutics has a 1-year low of $19.17 and a 1-year high of $53.24.

Several institutional investors have recently bought and sold shares of the company. Woodford Investment Management Ltd acquired a new position in shares of Autolus Therapeutics during the 2nd quarter worth about $42,643,000. Capital International Investors acquired a new position in shares of Autolus Therapeutics during the 3rd quarter worth about $14,745,000. Sphera Funds Management LTD. boosted its stake in shares of Autolus Therapeutics by 68.3% during the 3rd quarter. Sphera Funds Management LTD. now owns 296,251 shares of the company’s stock worth $8,935,000 after buying an additional 120,206 shares during the last quarter. Baker BROS. Advisors LP acquired a new position in shares of Autolus Therapeutics during the 2nd quarter worth about $6,304,000. Finally, Partner Fund Management L.P. boosted its stake in shares of Autolus Therapeutics by 11.0% during the 3rd quarter. Partner Fund Management L.P. now owns 219,628 shares of the company’s stock worth $6,736,000 after buying an additional 21,754 shares during the last quarter. Institutional investors own 44.20% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Further Reading: What is a balanced fund?

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit